Literature DB >> 17063185

Interferons, immunity and cancer immunoediting.

Gavin P Dunn1, Catherine M Koebel, Robert D Schreiber.   

Abstract

A clear picture of the dynamic relationship between the host immune system and cancer is emerging as the cells and molecules that participate in naturally occurring antitumour immune responses are being identified. The interferons (IFNs) - that is, the type I IFNs (IFNalpha and IFNbeta) and type II IFN (IFNgamma) - have emerged as central coordinators of tumour-immune-system interactions. Indeed, the decade-old finding that IFNgamma has a pivotal role in promoting antitumour responses became the focus for a renewed interest in the largely abandoned concept of cancer immunosurveillance. More recently, type I IFNs have been found to have distinct functions in this process. In this Review, we discuss the roles of the IFNs, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17063185     DOI: 10.1038/nri1961

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  589 in total

Review 1.  Macrophages as mediators of tumor immunosurveillance.

Authors:  Siddhartha Jaiswal; Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Trends Immunol       Date:  2010-05-07       Impact factor: 16.687

2.  Interferon gamma-induced human guanylate binding protein 1 inhibits mammary tumor growth in mice.

Authors:  Karoline Lipnik; Elisabeth Naschberger; Nathalie Gonin-Laurent; Petra Kodajova; Helga Petznek; Stefanie Rungaldier; Simonetta Astigiano; Silvano Ferrini; Michael Stürzl; Christine Hohenadl
Journal:  Mol Med       Date:  2010-02-05       Impact factor: 6.354

Review 3.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

4.  hCAF1/CNOT7 regulates interferon signalling by targeting STAT1.

Authors:  Clément Chapat; Chloé Kolytcheff; Muriel Le Romancer; Didier Auboeuf; Pierre De La Grange; Kamel Chettab; Stéphanie Sentis; Laura Corbo
Journal:  EMBO J       Date:  2013-02-05       Impact factor: 11.598

5.  Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.

Authors:  Benjamin Joachim Schmiedel; Antje Werner; Julia Steinbacher; Tina Nuebling; Corina Buechele; Ludger Grosse-Hovest; Helmut Rainer Salih
Journal:  Mol Ther       Date:  2013-02-05       Impact factor: 11.454

6.  Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells.

Authors:  Michael Y Gerner; Matthew F Mescher
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  Tumor-derived mutations in the gene associated with retinoid interferon-induced mortality (GRIM-19) disrupt its anti-signal transducer and activator of transcription 3 (STAT3) activity and promote oncogenesis.

Authors:  Shreeram C Nallar; Sudhakar Kalakonda; Daniel J Lindner; Robert R Lorenz; Eric Lamarre; Xiao Weihua; Dhananjaya V Kalvakolanu
Journal:  J Biol Chem       Date:  2013-02-05       Impact factor: 5.157

8.  Novel identification of STAT1 as a crucial mediator of ETV6-NTRK3-induced tumorigenesis.

Authors:  Jinah Park; Junil Kim; Bora Park; Kyung-Min Yang; Eun Jin Sun; Cristina E Tognon; Poul H Sorensen; Seong-Jin Kim
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

9.  Use of antigen-primed dendritic cells for inducing antitumor immune responses in vitro in patients with non-small cell lung cancer.

Authors:  Irina Obleukhova; Nataliya Kiryishina; Svetlana Falaleeva; Julia Lopatnikova; Vasiliy Kurilin; Vadim Kozlov; Aleksander Vitsin; Andrey Cherkasov; Ekaterina Kulikova; Sergey Sennikov
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

Review 10.  Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.

Authors:  Julie R Brahmer; Drew M Pardoll
Journal:  Cancer Immunol Res       Date:  2013-07-22       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.